BioFluidica

07/17/2023

We are seeking pregnant women 18 years and older in the early stages of pregnancy, specifically between 7-13 weeks, to participate in a prenatal blood screening study. As a token of appreciation, participants will earn $100 and receive a gender reveal!

Visit biofluidica.com/prenatal-study to learn more and sign up!

Help us advance non-invasive prenatal screening!

Prenatal Blood Screening Study Help us advance Non-invasive Prenatal Screening 18+ YEARS OLD 7-13 WEEKS GESTATION SAN DIEGO, CA ONLY DONATE SMALL VOLUME OF BLOOD We are currently seeking pregnant women aged 18 years and older in the early stages of pregnancy, specifically between 7-13 weeks. This in...

06/02/2023

Visit us tomorrow at Booth 27172 at ASCO 2023 in Chicago to learn about LiquidScan and Next-Generation Liquid Biopsy.

https://biofluidica.com/

06/01/2023

Introducing LiquidScan by BioFluidica, an advanced enrichment platform designed for downstream analysis of CTCs and Exosome subtypes in liquid biopsies. LiquidScan employs an innovative affinity catch-and-release technique to enhance the concentration of these elusive biomarkers found in blood. By surpassing the limit of detection for subsequent molecular analysis methods, LiquidScan enables comprehensive examination of these rare biomarkers. Discover more about LiquidScan and the cutting-edge Next-Generation Liquid Biopsy at BioFluidica's Booth 27172 during ASCO 2023 in Chicago from June 3rd to 5th.

https://biofluidica.com/

05/31/2023

Visit BioFluidica Booth 27172 at ASCO 2023 this weekend in Chicago (June 3-5) to learn about LiquidScan and Next-Generation Liquid Biopsy.

https://biofluidica.com/

05/30/2023

BioFluidica LiquidScan is an affinity catch-and-release enrichment platform for liquid biopsy downstream analysis for CTCs and Exosome subtypes. For these rare biomarkers in blood, for example, LiquidScan raises the relative concentration of the biomarker above the limit of detection for downstream molecular analysis methods. Visit BioFluidica Booth 27172 at ASCO 2023 in Chicago June 3-5 to learn about LiquidScan and Next-Generation Liquid Biopsy.

https://biofluidica.com/

05/24/2023

Plan a visit to the upcoming ASCO 2023 Conference to learn about BioFluidica Products and Services to enrich Rare Cells (CTCs) and EVs from Liquid Biopsy. Contact [email protected] to schedule a meeting at ASCO.

04/25/2023

The AACR Annual Meeting 2023 was a huge success! Visitors to our booth enjoyed learning about LiquidScan and how it provides fast, automated affinity-based rare cell (CTC) and specific exosome sub-type capture for cell- and exosome-based Liquid Biopsy. Also, congratulations to our visitors who won our raffle for the Beats Studio Earbuds!

www.biofluidica.com

04/18/2023

We had a successful poster session today at ! Dr. Yipeng Wang presented single cell multi-omics analysis using cell-based Liquid Biopsy. BioFluidica LiquidScan reproducibly, isolated viable CTCs in sufficient numbers from a patients' blood to enable analysis of DNA, RNA, and protein biomarkers on a single cell level. LiquidScan provided fast, automated CTC isolation to make the downstream molecular analysis feasible in clinical settings.

Don't forget to stop by booth #410 until 5 pm today and 9 am - 12:30 pm tomorrow!

www.biofluidica.com

04/17/2023

Stop by booth #410 at and learn about our next-generation liquid biopsy platform, LiquidScan, making cell-based and exosome-based liquid biopsy possible.

While visiting us, enter for your chance to win a pair of brand-new Studio Beats earbuds!

www.biofluidica.com

04/13/2023

BioFluidica will be presenting their research on single cell multi-omics analysis using cell-based Liquid Biopsy at AACR 2023 Tuesday, April 18th in Orlando, FL. The BioFluidica LiquidScan platform reproducibly, isolated viable CTCs in sufficient numbers from a patient’s blood to enable analysis of DNA, RNA, and protein biomarkers on a single cell level. LiquidScan provided fast, automated CTC isolation to make the downstream molecular analysis feasible in clinical settings.

Also, visit our booth #410 and enter for your chance to win a pair of brand-new Studio Beats earbuds!

www.biofluidica.com

04/11/2023

Professor Steven Soper, co-founder of BioFluidica, will be speaking on a panel discussion at AACR on April 19th at 10:45 am in Room W414. The potential clinical applications of liquid biopsy are vast and includes screening, detection of minimal residual disease and/or early relapse after curative intent treatment, monitoring response to therapy, identifying molecular targets for treatment, and identification of resistance mechanisms while on treatment. There has been a monumental advance in next generation of liquid biopsy tools. This session focuses on bringing not only the state of the art, but what is on the horizon of Liquid Biopsy field.

Visit our booth #410 and enter for your chance to win a pair of brand-new Studio Beats earbuds!

04/06/2023

The AACR Annual Meeting 2023 will bring scientists and clinicians together to create a “Vision for the Future”. At BioFluidica, we have created LiquidScan to make cell- and exosome-based cancer diagnostics possible from liquid biopsy. LiquidScan is the future of liquid biopsy.
www.biofluidica.com